TED "Taxus Element in Diabetics Registry" is a multi-country, multi-center, observational, open-label medical registry designed to electronically capture data, manage, monitor, and report in diabetic patients' outcomes receiving Paclitaxel eluting Taxus Element Stent.
TED is designed to be non experimental study, where all enrolled patients should be treated according to the current routine hospital practice and standards of care.
TED patient population are only those patients with diabetes mellitus suitable for drug-eluting stent implantation according to the applicable guidelines on percutaneous coronary interventions.
"The C.E. marked Paclitaxel eluting Taxus Element stent of (Boston Scientific, Natick, Massachusetts)"
Diabetes has always adversely affected the outcome of percutaneous coronary intervention (PCI) first angioplasty and then later stenting. Patients with diabetes mellitus are known to have a higher adverse event rate after PCI and stenting compared with those without diabetes. This is mainly due to increased restenosis and subsequent need for repeat revascularization.
Five countries from across the Middle-east, North Africa and Asia are participating in TED study:
- Saudi Arabia - United Arab Emirates - Lebanon - Tunisia - Iran - Pakistan
- Saudi Arabia
- United Arab Emirates